Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials

Markov, Oleg V.; Миронова, Н. Л.; Vlassov, Valentin V.; Zenkova, Marina A.

doi:10.32607/20758251-2017-9-3-27-38

Cited by 8 publications

(8 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different immune-stimulatory molecules can also be introduced to EVs to modulate anti-tumor immunity and act as EV-based tumor vaccines [ 159 ]. Tumor cells producing the EVs can be engineered to express specific cytokines/chemokines that have an immunomodulating effect on the tumor microenvironment [ 159 , 160 ].…”

Section: Evs For Cancer Therapymentioning

confidence: 99%

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy

Mathew

Zade

Mezghani

et al. 2020

Cancers

View full text Add to dashboard Cite

Extracellular vesicles (EVs), including exosomes and microvesicles, are membrane-bound vesicles secreted by most cell types during both physiologic conditions as well in response to cellular stress. EVs play an important role in intercellular communication and are emerging as key players in tumor immunology. Tumor-derived EVs (TDEs) harbor a diverse array of tumor neoantigens and contain unique molecular signature that is reflective of tumor’s underlying genetic complexity. As such they offer a glimpse into the immune tumor microenvironment (TME) and have the potential to be a novel, minimally invasive biomarker for cancer immunotherapy. Immune checkpoint inhibitors (ICI), such as anti- programmed death-1(PD-1) and its ligand (PD-L1) antibodies, have revolutionized the treatment of a wide variety of solid tumors including head and neck squamous cell carcinoma, urothelial carcinoma, melanoma, non-small cell lung cancer, and others. Typically, an invasive tissue biopsy is required both for histologic diagnosis and next-generation sequencing efforts; the latter have become more widespread in daily clinical practice. There is an unmet need for noninvasive or minimally invasive (e.g., plasma-based) biomarkers both for diagnosis and treatment monitoring. Targeted analysis of EVs in biospecimens, such as plasma and saliva could serve this purpose by potentially obviating the need for tissue sample. In this review, we describe the current challenges of biomarkers in cancer immunotherapy as well as the mechanistic role of TDEs in modulating antitumor immune response

show abstract

Section: Evs For Cancer Therapymentioning

confidence: 99%

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy

Mathew

Zade

Mezghani

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Several decades of intensive investigations of anti-tumor DC-based vaccines have revealed their high efficiency in various murine tumor models (Lin et al, 2015; Markov et al, 2017) and human xenografts in immunodeficient mice (Liu et al, 2019).…”

Section: Dendritic Cells: a Brief History Of Anti-tumor Dc-based Vaccmentioning

confidence: 99%

Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles—A Novel Strategy for Enhancement of the Anti-tumor Immune Response

2019

View full text Add to dashboard Cite

Dendritic cell (DC)-based anti-tumor vaccines have great potential for the treatment of cancer. To date, a large number of clinical trials involving DC-based vaccines have been conducted with a view to treating tumors of different histological origins. However, DC-based vaccines had several drawbacks, including problems with targeted delivery of tumor antigens to DCs and prolong storage of cellular vaccines. Therefore, the development of other immunotherapeutic approaches capable of enhancing the immunogenicity of existing DC-based vaccines or directly triggering anti-tumor immune responses is of great interest. Extracellular vesicles (EVs) are released by almost all types of eukaryotic cells for paracrine signaling. EVs can interact with target cells and change their functional activity by delivering different signaling molecules including mRNA, non-coding RNA, proteins, and lipids. EVs have potential benefits as natural vectors for the delivery of RNA and other therapeutic molecules targeted to DCs, T-lymphocytes, and tumor cells; therefore, EVs are a promising entity for the development of novel cell-free anti-tumor vaccines that may be a favourable alternative to DC-based vaccines. In the present review, we discuss the anti-tumor potential of EVs derived from DCs, tumors, and other cells. Methods of EV isolation are systematized, and key molecules carried by EVs that are necessary for the activation of a DC-mediated anti-tumor immune response are analyzed with a focus on the RNA component of EVs. Characteristics of anti-tumor immune responses induced by EVs in vitro and in vivo are reviewed. Finally, perspectives and challenges with the use of EVs for the development of anti-tumor cell-free vaccines are considered.

show abstract

“…DCs are professional APCs which present antigen material to T lymphocytes activating an antigen-specific T-lymphocyte immune response. Anti-tumor DC-based vaccines have revealed their high efficiency in various murine tumor models (111,112) and human xenografts in immunodeficient mice (113).…”

Section: Ev Applications In Promoting Gvl and In Preventing Disease Rmentioning

confidence: 99%

Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications

et al. 2020

View full text Add to dashboard Cite

Extracellular vesicles (EVs) play an important role in the cellular crosstalk by transferring bioactive molecules through biological barriers from a cell to another, thus influencing recipient cell functions and phenotype. Therefore, EVs are increasingly being explored as biomarkers of disease progression or response to therapy and as potential therapeutic agents in different contexts including in hematological malignancies. Recently, an EV role has emerged in allogeneic hematopoietic cell transplantation (allo-HCT) as well. Allogeneic hematopoietic cell transplantation often represents the only curative option in several hematological disorders, but it is associated with potentially life-threatening complications that can have a significant impact on clinical outcomes. The most common complications have been well-established and include graft-versus-host disease and infections. Furthermore, relapse remains an important cause of treatment failure. The aim of this review is to summarize the current knowledge, the potential applications, and clinical relevance of EVs in allo-HCT. Herein, we will mainly focus on the immune-modulating properties of EVs, in particular those derived from mesenchymal stromal cells, as potential therapeutic strategy to improve allo-HCT outcome. Moreover, we will briefly describe the main findings on EVs as biomarkers to monitor graft-versushost disease onset and tumor relapse.

show abstract

Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials

Cited by 8 publications

References 91 publications

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy

Extracellular Vesicles as Biomarkers in Cancer Immunotherapy

Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles—A Novel Strategy for Enhancement of the Anti-tumor Immune Response

Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications

Contact Info

Product

Resources

About